Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00968968
First received: August 27, 2009
Last updated: August 7, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)